Phase 2 RCT | Adjuvant intravesical chemohyperthermia not better than passive chemotherapy in patients with intermediate-risk non–muscle-invasive bladder cancer.

Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial – European Urology

Commentary on Twitter

No benefit of adjuvant intravesical hyperthermic chemo (CHT) for intermediate-risk non–muscle-invasive bladder cancer
?DFS @ 24 mo was 61% vs 60%
?Patients treated with CHT were less likely to complete their treatment @EUplatinum @OncoAlert @Uroweb https://t.co/q8lB2MxBFf pic.twitter.com/E8Ay5hirBb

— Yüksel Ürün (@DrYukselUrun) August 22, 2022

Under a Creative Commons license